Supplementary Figure 1 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve &Lt;i>alk-, ROS1-</i>, or &Lt;i>egfr</i>-Altered Non–small Cell Lung Cancer

Hirohisa Kano,Eiki Ichihara, Hiromi Watanabe,Kazuya Nishii,Chihiro Ando,Takamasa Nakasuka,Kiichiro Ninomiya, Yoshio Kato, Toshio Kubo,Kammei Rai, Kadoaki Ohashi,Katsuyuki Hotta, Masaaki Tabata, Yasuhiro Maeda,Katsuyuki Kiura

openalex（2023）

引用 0|浏览0

暂无评分

摘要

Supplementary Figure 1. phospho-RTK array in PC-9 cells phospho-RTK array in PC-9 cells treated with 100 nM of the EGFR TKI erlotinib for up to 96 h. Multiple RTKs were gradually activated over time.

查看译文

关键词

Protein Tyrosine Phosphatases

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Figure 1 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve &Lt;i&gt;alk-, ROS1-&lt;/i&gt;, or &Lt;i&gt;egfr&lt;/i&gt;-Altered Non–small Cell Lung Cancer

Supplementary Figure 1 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve &Lt;i>alk-, ROS1-</i>, or &Lt;i>egfr</i>-Altered Non–small Cell Lung Cancer